Cubist Systematic Strategies, LLC Chinook Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $1.39 Million - $2.88 Million	74,662 Added 2464.09%	77,692 $2.98 Million
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $621,312 - $773,394	-28,858 Reduced 90.5%	3,030 $70,000
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $514,430 - $755,215	-27,613 Reduced 46.41%	31,888 $835,000
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $1.76 Million - $2.35 Million	-100,558 Reduced 62.83%	59,501 $1.17 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $1.99 Million - $2.98 Million	158,409 Added 9600.55%	160,059 $2.8 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $670,728 - $931,318	-55,801 Reduced 97.13%	1,650 $27,000
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $614,151 - $966,900	57,451 New	57,451 $937,000
Q3 2021 Nov 15, 2021	SELL	$11.5 - $14.86 $22,896 - $29,586	-1,991 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $27,077 - $37,789	1,991 New	1,991 $28,000
Q1 2021 May 17, 2021	SELL	$14.17 - $19.11 $5,370 - $7,242	-379 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $4,510 - $7,924	379 New	379 $6,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.